THURSDAY, Jan. 31, 2019 — The first generic version of the widely used Advair Diskus inhaler for asthma and chronic obstructive pulmonary disease (COPD) has won U.S. Food and Drug Administration approval. This approval “is part of our longstanding commitment to advance access to lower cost, high-quality generic alternatives,” said Dr. Janet Woodcock, director of